FDA Grants Fast Track Status to Verastem’s KRAS G12D Inhibitor for Lung Cancer
Event summary
- Verastem Oncology’s VS-7375 received FDA Fast Track Designation for KRAS G12D-mutated NSCLC after platinum-based chemotherapy and anti-PD-(L)1 therapy.
- The designation follows prior Fast Track status for pancreatic cancer, expanding VS-7375’s clinical focus.
- Phase 2 trial TARGET-D 202 is evaluating VS-7375 in advanced NSCLC, including patients with brain metastases.
- VS-7375 is a selective KRAS G12D (ON/OFF) inhibitor, targeting a mutation present in 5% of NSCLC cases.
The big picture
Verastem’s Fast Track designation for VS-7375 underscores the urgency in addressing KRAS G12D-mutated cancers, a subset with limited treatment options. The FDA’s expedited pathway reflects both the unmet need in NSCLC and the potential of VS-7375’s unique mechanism. With ongoing trials in pancreatic and colorectal cancers, Verastem is betting on a multi-indication strategy to maximize the drug’s commercial potential.
What we're watching
- Clinical Efficacy
- Whether VS-7375’s dual ON/OFF inhibition mechanism translates to superior outcomes in NSCLC compared to existing KRAS inhibitors.
- Regulatory Momentum
- The pace at which Verastem advances VS-7375 through Phase 2 trials across multiple cancer types, leveraging Fast Track status.
- Commercial Strategy
- How Verastem positions VS-7375 in a competitive landscape, particularly against emerging KRAS-targeting therapies.
Related topics